Modeling energy intake and body weight effects of a long-acting amylin analogue

Area of Science:

• Pharmacology
• Endocrinology
• Obesity Research

Background:

• Anti-obesity drug efficacy is limited by appetite control feedback, leading to tolerance.
• Rodent studies for anti-obesity drug development face challenges in EI study design and interpretation.
• Amylin analogues represent a potential therapeutic strategy for weight management.

Purpose of the Study:

• To investigate the effects of a synthetic long-acting amylin analogue (LAMY) on energy intake (EI) and body weight (BW) in lean and diet-induced obese (DIO) rats.
• To develop and evaluate a population model to describe LAMY pharmacodynamics and inform dosing strategies.
• To assess the development of tolerance to LAMY treatment over time.

Main Methods:

• Six pharmacodynamic (PD) studies involving 173 rats were conducted.
• LAMY was administered subcutaneously at various doses and regimens.
• EI and BW were monitored daily; plasma LAMY concentrations were measured.
• A population model incorporating homeostatic feedback and a turnover model was developed.

Main Results:

• LAMY treatment resulted in a dose-dependent reduction in EI and BW.
• Tolerance to LAMY's effects was observed with multiple dosing.
• The developed population model adequately described the observed EI and BW changes.
• Model predictions were validated in a toxicology study.

Conclusions:

• LAMY demonstrates potential as an anti-obesity agent, but tolerance necessitates careful dosing strategies.
• The population model is a valuable tool for optimizing rodent study design and interpretation in anti-obesity drug development.
• Understanding feedback regulation is crucial for overcoming drug tolerance in obesity pharmacotherapy.